---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179418"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:55:04.339486+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q2 2025 net loss $27.0M; cash $177.3M; Phase 3 CoMpass nearing enrollment end

## Summary
- Net loss $27.0M in Q2 2025 vs $20.3M in Q2 2024; R&D expenses rose to $22.9M from $16.9M.
- Cash and marketable securities $177.3M; $75M equity financing closed; cash runway into first half 2027.
- Phase 3 CoMpass trial in early choroidal melanoma actively enrolling; >240 patients pre-screened; enrollment may complete by end of 2025.
- Phase 1b/2 NMIBC trial actively enrolling; new bel-sar formulation patent filed for convenient in-office use.
- Phase 2 trial in metastases to choroid protocol amended to include all solid tumors; initial data expected 2025.

## SEC filing metadata
- accession: 0001193125-25-179418
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/0001193125-25-179418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/aura-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179418
- JSON: https://secwatch.observer/filing/0001193125-25-179418.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.